Third doses of the vaccine are recommended for those aged 12 and up, and a fourth dose was recently recommended for people over 50.
In the phase 2/3 trial, the companies analyzed data from 140 children aged five through 11, approximately six months after the second dose. They also analyzed blood sera from a group of 30 individuals, finding that a third dose caused a 36-fold increase in levels of infection-blocking neutralizing antibodies against Omicron, compared to two doses.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: